![CEimpact Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5e/ae/42/5eae4208-b706-0adc-12fb-75292fc9ea63/mza_14075584767013252581.jpg/100x100bb.jpg)
Famotidine and Lockdowns - COVID Solutions?
CEimpact Podcast
English - March 28, 2022 09:00 - 24 minutes - 17.1 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
The world of COVID-19 is always changing. Join Geoff Wall for a rapid fire of updates regarding famotidine, lockdowns, and ivermectin as evaluated for efficacy in COVID-19.
The GameChangers
The use of high-dose famotidine in the treatment of COVID-19 has demonstrated moderate safety, but questionable efficacy. Additionally, a recent meta-analysis examining the efficacy of lockdown on the spread of COVID-19 had several limitations that should be taken into consideration.
Show Segments
00:00 – Introductions
01:56 – Famotidine in the Treatment of COVID-19
10:52 – Effects of Lockdown on COVID-19 Mortality
18:26 – Ivermectin Treatment of COVID-19 in High-Risk Patients
23:45 – Closing Remarks
Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Redeem your CPE or CME credit here!
Pharmacist membersCMENeed a membership?
Join for CPE CreditJoin for CME CreditReferences and resources:
References and resources:1. Oral Famotidine Versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blind, Data-Intense, Phase 2 Clinical Trial
2. A Literature Review and Meta-Analysis of the Effects of Lockdowns on COVID-19 Mortality. Pre-Publication.
3. Efficacy of Ivermectin Treatment on Disease Progression Among Adults with Mild to Moderate COVID-19 and Comorbidities
Continuing Education Information:
Learning Objectives:
1. Describe the latest information on masks and other non-pharmacologic interventions to halt the spread of COVID-192. Discuss the recent randomized controlled trial evaluating famotidine use in early COVID-19 positive patients
Dr. Wall is a member of the Janssen Speaker's Bureau.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-142-H01-P
Initial release date: 03/28/22
Expiration date: 03/28/2023